

Navigating the evolving mCRPC landscape: Your questions, their answers

Monday, 23 October 2023, 13:00–14:30 CEST

León Auditorium, Hall 7, IFEMA MADRID,
Madrid, Spain



Alicia Morgans



Elena Castro



Boris Hadaschik



Irene Burger

- **Welcome, introduction and educational objectives**
Alicia Morgans (Chair)
- **Treatment of advanced prostate cancer: Frequently asked questions**
Expert discussion of treatment options in mCRPC with a focus on radioligand therapy (RLT)
All
- **Patient case discussion**
All
- **Closing remarks**
Alicia Morgans (Chair)

This scientific program and/or material was developed for use outside of the US, intended for non-US HCPs licensed to prescribe medicine, and is to be used in accordance with local laws and regulations. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.